bioMérieux and GSK team up for breast cancer theranostic
This article was originally published in Clinica
Executive Summary
French diagnostics company bioMérieux is collaborating with pharma giant GlaxoSmithKline (GSK) to develop a predictive test that will provide more customised treatment for breast cancer patients. Both companies will co-fund the development activities. The test, based on emerging biomarkers, will be designed for use in both adjuvant and metastatic breast cancer cases.